NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...

High performance fluorescently conjugated antibodies designed for flow cytometry and beyond help researchers improve data reliability and streamline experimental design. As for many antibody-based ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

Scientists have turned to antibodies, and their natural targeting affinity, as a potential solution. Antibody-drug conjugates (ADC) combine the tumor-targeting potential of antibodies with the potency ...

Sanofi has developed a simpler way to create site-specific antibody-to-mannose-6-phosphate (M6P) conjugates that eliminates the need for enzyme remodeling. This more straightforward method makes ...

ZW191 is a novel drug called a folate receptor-alpha (FRα) targeted topoisomerase I inhibitor antibody-drug conjugate, according to a news release from Zymeworks, the drug’s manufacturer. An ...

Collaborations announced for antibody-drug conjugate development Merck KGaA and Merck & Co. announce end-of-year pacts to develop ADC cancer treatments by Shi En Kim ...

TOPLINE: ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...

GSK’227 (also known as HS-20093) is a novel antibody-drug conjugate (ADC) composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer." In this new editorial ...

TORL-1-23, a CLDN6–targeted antibody-drug conjugate (ADC), generated responses and was well tolerated in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian ...